The growth hormone receptor: Mechanism of activation and clinical implications

Nature Reviews Endocrinology

Volumn 6, Issue 9, 2010, Pages 515-525

  Brooks, Andrew J ^a   Waters, Michael J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE; JANUS KINASE 2; MECASERMIN RINFABATE; PROTEIN TYROSINE KINASE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C;

ACROMEGALY; AUTOCRINE EFFECT; CELL TRANSFORMATION; CHRONIC KIDNEY DISEASE; CROHN DISEASE; CYSTIC FIBROSIS; DNA POLYMORPHISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FIBROMYALGIA; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE MUTATION; GIGANTISM; GROWTH HORMONE DEFICIENCY; HORMONE RECEPTOR INTERACTION; HUMAN; HYPOPITUITARISM; JUVENILE RHEUMATOID ARTHRITIS; KIDNEY POLYCYSTIC DISEASE; LARON SYNDROME; LOSS OF FUNCTION MUTATION; NEOPLASM; NONHUMAN; NOONAN SYNDROME; POINT MUTATION; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DOMAIN; PROTEIN LOCALIZATION; RECEPTOR GENE; REVIEW; SHORT STATURE; SHORT STATURE HOMEOBOX PROTEIN DEFICIENCY; SIGNAL TRANSDUCTION; SMALL FOR DATE INFANT; THYMUS ATROPHY; TURNER SYNDROME; UNSPECIFIED SIDE EFFECT; WASTING SYNDROME;

ANIMALS; HORMONE ANTAGONISTS; HUMAN GROWTH HORMONE; HUMANS; JANUS KINASE 2; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MUTATION; PHOSPHORYLATION; RECEPTORS, SOMATOTROPIN;

EID: 77955921088     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.123     Document Type: Review

References (141)

1. Waxman, D. J. & O'Connor, C. Growth hormone regulation of sex-dependent liver gene expression. Mol. Endocrinol. 20, 2613-2629 (2006).
2. Lichanska, A. M. & Waters, M. J. How growth hormone controls growth, obesity and sexual dimorphism. Trends Genet. 24, 41-47 (2008).
3. Lanning, N. J. & Carter-Su, C. recent advances in growth hormone signaling. Rev. Endocr. Metab. Disord. 7, 225-235 (2006).
4. Waters, M. J. et al. Growth hormone as a cytokine. Clin. Exp. Pharmacol. Physiol. 26, 760-764 (1999).
5. rowland, J. E. et al. In vivo analysis of growth hormone receptor signaling domains and their associated transcripts. Mol. Cell. Biol. 25, 66-77 (2005).
6. Barclay, J. L. et al. In vivo targeting of the growth hormone receptor (GHr) Box1 sequence demonstrates that the GHr does not signal exclusively through JAK2. Mol. Endocrinol. 24, 204-217 (2010).
7. Laron, Z., Ginsberg, S. & Webb, M. Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion. Growth Horm. IGF Res. 18, 434-438 (2008).
8. Slot, K. A. et al. reduced recruitment and survival of primordial and growing follicles in GH-receptor deficient mice. Reproduction 131, 525-532 (2006).
9. Sotiropoulos, A. et al. Growth hormone promotes skeletal muscle cell fusion independent of insulin-like growth factor 1 up-regulation. Proc. Natl Acad. Sci. USA 103, 7315-7320 (2006).
10. Wang, J., Zhou, J., Cheng, C. M., Kopchick, J. J. & Bondy, C. A. Evidence supporting dual, IGF-1 independent and IGF-1 dependent, roles for GH in promoting longitudinal bone growth. J. Endocrinol. 180, 247-255 (2004).
11. Lindahl, A., Isgaard, J., Carlsson, L. & Isaksson, O. G. Differential effects of growth hormone and insulin-like growth factor 1 on colony formation of epiphyseal chondrocytes in suspension culture in rats of different ages. Endocrinology 121, 1061-1069 (1987). (Pubitemid 17139160)
12. Blackmore, D. G., Golmohammadi, M. G., Large, B., Waters, M. J. & rietze, R. L. Exercise increases neural stem cell number in a growth hormone-dependent manner, augmenting the regenerative response in aged mice. Stem Cells 27, 2044-2052 (2009).
13. McLenachan, S., Lum, M. G., Waters, M. J. & Turnley, A. M. Growth hormone promotes proliferation of adult neurosphere cultures. Growth Horm. IGF Res. 19, 212-218 (2009).
14. rosenbloom, A. L. Insulin-like growth factor-1 therapy of short stature. J. Pediatr. Endocrinol. Metab. 21, 301-315 (2008).
15. Lupu, F., Terwilliger, J. D., Lee, K., Segre, G. v. & Efstradiatis, A. roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev. Biol. 229, 141-162 (2001).
16. Møller, N. & Jørgensen, J. O. Effects of growth hormone on glucose, lipid and protein metabolism in human subjects. Endocr. Rev. 30, 152-177 (2009).
17. Simon, D., Léger, J. & Carel, J. C. Optimal use of growth hormone therapy for maximizing adult height in children born small for gestational age. Best Pract. Res. Clin. Endocrinol. Metab. 22, 525-537 (2008).
18. Labarta, J. I. et al. Growth and growth hormone treatment in short stature children born small for gestational age. Pediatr. Endocrinol. Rev. 6 (Suppl. 3), 350-357 (2009).
19. Bakker, B., Frane, J., Anhalt, H., Lippe, B. & rosenfeld, R. G. Height velocity targets from the national cooperative growth study for first-year growth hormone responses in short children. J. Clin. Endocrinol. Metab. 93, 352-357 (2008).
20. Hokken-Koelega, A. C. et al. Placebo-controlled, double blind, cross over trial of growth hormone treatment in prepubertal children with chronic renal failure. Lancet 338, 585-590 (1991).
21. Mehls, O. et al. Growth hormone treatment in short children with chronic kidney disease. Acta Paediatr. 97, 1159-1164 (2008).
22. Blum, W. F. et al. Growth hormone is effective in treatment of short stature associated with short stature homeobox-containing gene deficiency: Two year results of a randomized, controlled, multicenter trial. J. Clin. Endocrinol. Metab. 92, 219-228 (2007).
23. Bryant, J., Baxter, L., Cave, C. B. & Milne, R. recombinant GH for idiopathic short stature in children and adolescents. Cochrane Database Systematic Reviews, Issue 3. Art No.: CD004440. doi:10.1002/14651858. CD004440.pub2 (2007).
24. Cohen, P. et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature. J. Clin. Endocrinol. Metab. 93, 4210-4217 (2008).
25. romano, A. A. et al. Growth response, near adult height and patterns of growth and puberty in patients with Noonan syndrome treated with growth hormone. J. Clin. Endocrinol. Metab. 94, 2338-2344 (2009).
26. Davenport, M. L. et al. Growth hormone treatment of early growth failure in toddlers with Turner syndrome: a randomized, controlled, multicenter trial. J. Clin. Endocrinol. Metab. 92, 3406-3416 (2007).
27. Goldstone, A. P. et al. recommendations for the diagnosis and management of Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 93, 4183-4197 (2008).
28. Burman, P., ritzén, E. M. & Lindgren, A. C. Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH. Endocr. Rev. 22, 787-799 (2001).
29. Simon, D. & Bechtold, S. Effects of growth hormone treatment on growth in children with juvenile idiopathic arthritis. Horm. Res. 72 (Suppl. 1), 55-59 (2009).
30. Feldt-rasmussen, B. & El Nahas, M. Potential role of growth factors with particular focus on growth hormone and insulin-like growth factor 1 in the management of chronic kidney disease. Semin. Nephrol. 29, 50-58 (2009).
31. Tesselaar, K. & Miedema, F. Growth hormone resurrects adult human thymus during HIv-1 infection. J. Clin. Invest. 118, 844-847 (2008).
32. Burger, A. G., Monson, J. P., Colao, A. M. & Klibanski, A. Cardiovascular risk in patients with growth hormone deficiency: effects of growth hormone substitution. Endocr. Pract. 12, 682-689 (2006).
33. Boschetti, M. et al. replacement therapy and cardiovascular diseases. J. Endocrinol. Invest. 31 (9 Suppl.), 85-90 (2008).
34. Widdowson, W. M. & Gibney, J. The effect of GH replacement on exercise capacity in patients with GH deficiency: a metaanalysis. J. Clin. Endocrinol. Metab. 93, 4413-4417 (2008).
35. Saller, B. et al. Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults-comparison between Sweden, The Netherlands and Germany. Eur. J. Endocrinol. 154, 843-850 (2006).
36. Kolibianakis, E. M., venetis, C. A., Diedrich, K., Tarlatzis, B. C. & Griesinger, G. Addition of growth hormone to gonadotrophins in ovarian stimulation of poor responders treated by in vitro fertilization: a systematic review and meta-analysis. Hum. Reprod. Update 15, 613-622 (2009).
37. Melmed, S. Acromegaly pathogenesis and treatment. J. Clin. Invest. 119, 3189-3202 (2009).
38. Thankamony G. N., Dunger, D. B. & Acerini, C. L. Pegvisomant: current and potential novel therapeutic applications. Expert Opin. Biol. Ther. 9, 1553-1563 (2009).
39. Wilkinson-Berka, J. L. et al. An antisense oligonucleotide targeting the GH receptor inhibits neovascularization in a mouse model of retinopathy. Mol. Vis. 13, 1529-1538 (2007).
40. Luft, R. The use of hypophysectomy in juvenile diabetes mellitus with vascular complications. Diabetes 11, 461-462 (1962).
41. Waters, M. J. & Barclay, J. L. Does growth hormone drive breast and other cancers? Endocrinology 148, 4533-4535 (2007).
42. Divisova, J. et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res. Treat. 98, 315-327 (2006).
43. Dagnaes-Hansen, F., Duan, H., rasmussen, L. M., Friend, K. E. & Flyvbjerg, A. Growth hormone receptor antagonist administration inhibits growth of human colorectal carcinoma in nude mice. Anticancer Res. 24, 3735-3742 (2004).
44. Godowski, P. J. et al. Characterization of the human growth hormone receptor gene and demonstration of a partial deletion in two patients with Laron-type dwarfism. Proc. Natl Acad. Sci. USA 86, 8083-8087 (1989).
45. De vos, A. M., Ultsch, M. & Kossiakoff, A. A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306-312 (1992).
46. Waters, M. J. In Handbook of Physiology vol.5 Ch 13, section 7 (eds Kostyo, J. L. & Goodman, H. M.) 397-444 (Oxford Press, Oxford, 1999).
47. Wells, J. A. Binding in the growth hormone receptor complex. Proc. Natl Acad. Sci. USA 93, 1-6 (1996).
48. Fuh, G. et al. rational design of potent antagonists to the human growth hormone receptor. Science 256, 1677-1680 (1992).
49. Cunningham, B. C. et al. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 254, 821-825 (1991).
50. Brown, R. J. et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat. Struct. Mol. Biol. 12, 814-821 (2005).
51. Gent, J., van Kerkhof, P., roza, M., Bu, G. & Strous, G. J. Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis. Proc. Natl Acad. Sci. USA 99, 9858-9863 (2002).
52. rowlinson, S. W. et al. Activation of chimeric and full-length growth hormone receptors by growth hormone receptor monoclonal antibodies. A specific conformational change may be required for full-length receptor signaling. J. Biol. Chem. 273, 5307-5314 (1998).
53. Gadd, S. L. & Clevenger, C. v. Ligandindependent dimerization of the human prolactin receptor isoforms: functional implications. Mol. Endocrinol. 20, 2734-2746 (2006).
54. Livnah, O. et al. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science 283, 987-990 (1999).
55. Constantinescu, S. N. et al. Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc. Natl Acad. Sci. USA 98, 4379-4384 (2001).
56. Wan, Y., Zheng, Y. Z., Harris, J. M., Brown, R. & Waters, M. J. Epitope map for a GH receptor agonist monoclonal antibody, MAb 263. Mol. Endocrinol. 17, 2240-2250 (2003).
57. Poger, D. & Mark, A. E. Turning the growth hormone receptor on: evidence that hormone binding induces subunit rotation. Proteins 78, 1163-1174 (2010).
58. Kuo, C. B., Coss, D. & Walker, A. M. Prolactin receptor antagonists. Endocrine 9, 121-131 (1998).
59. Constantinescu, S. N., Huang, L. J., Nam, H. & Lodish, H. F. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol. Cell 7, 377-385 (2001).
60. Liu, W., Kawahara, M., Ueda, H. & Nagamune, T. Construction of a fluorescein-responsive chimeric receptor with strict ligand dependency. Biotechnol. Bioeng. 101, 975-984 (2008).
61. Livnah, O. et al. An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat. Struct. Biol. 5, 993-1004 (1998).
62. Syed, R. S. et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature 395, 511-516 (1998).
63. Liu, W., Kawahara, M., Ueda, H. & Nagamune, T. The influence of domain structures on the signal transduction of chimeric receptors derived from the erythropoietin receptor. J. Biochem. 145, 575-584 (2009).
64. Jin, H., Lanning, N. J. & Carter-Su, C. JAK2, but not Src family kinases, is required for STAT, ErK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma cells. Mol. Endocrinol. 22, 1825-1841 (2008).
65. rowlinson, S. W. et al. An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway. Nat. Cell Biol. 10, 740-747 (2008).
66. Zhang, F., Zhang, Q., Tengholm, A. & Sjöholm, A. Involvement of JAK2 and Src kinase tyrosine phosphorylation in human growth hormonestimulated increases in cytosolic free Ca2+ and insulin secretion. Am. J. Physiol. Cell Physiol. 291, C466-C475 (2006).
67. Lannutti, B. J. & Drachman, J. G. Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of hematopoietic cell lines and primary megakaryocytic progenitors. Blood 103, 3736-3743 (2004).
68. Tilbrook, P. A., Ingley, E., Williams, J. H., Hibbs, M. L. & Klinken, S. P. Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells. EMBO J. 16, 1610-1619 (1997).
69. Chin, H. et al. Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. Blood 91, 3734-3745 (1998).
70. Fresno vara, J. A., Carretero, M. v., Gerónimo, H., Ballmer-Hofer, K. & Martín-Pérez, J. Stimulation of c-Src by prolactin is independent of Jak2. Biochem. J. 345, 17-24 (2000).
71. Boudot, C. et al. Involvement of the Src kinase Lyn in phospholipase C-gamma 2 phosphorylation and phosphatidylinositol 3-kinase activation in Epo signalling. Biochem. Biophys. Res. Commun. 300, 437-442 (2003).
72. Liu, W., Kawahara, M., Ueda, H. & Nagamune, T. The influence of domain structures on the signal transduction of chimeric receptors derived from the erythropoietin receptor. J. Biochem. 145, 575-584 (2009).
73. Giordanetto, F. & Kroemer, R. T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng. 15, 727-737 (2002).
74. He, K. et al. Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling. Mol. Endocrinol. 17, 2211-2227 (2003).
75. Saharinen, P., vihinen, M. & Silvennoinen, O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell 14, 1448-1459 (2003).
76. Lacronique, v. et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278, 1309-1312 (1997).
77. Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790 (2005). (Pubitemid 40570926)
78. Lee, T. S. et al. Mechanisms of constitutive activation of Janus kinase 2-v617F revealed at the atomic level through molecular dynamics simulations. Cancer 115, 1692-1700 (2009).
79. Lu, X., Huang, L. J. & Lodish, H. F. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2v617F. J. Biol. Chem. 283, 5258-5266 (2008).
80. Zhao, L. et al. A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation. J. Biol. Chem. 284, 26988-26998 (2009).
81. Yang, N., Wang, X., Jiang, J. & Frank, S. J. role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation. Mol. Endocrinol. 21, 1642-1655 (2007).
82. Lu, X., Gross, A. W. & Lodish, H. F. Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains. J. Biol. Chem. 281, 7002-7011 (2006).
83. Onishi, M. et al. Identification of an oncogenic form of the thrombopoietin receptor MPL using retrovirus-mediated gene transfer. Blood 88, 1399-1406 (1996).
84. Ding, J. et al. The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity. Blood 114, 3325-3328 (2009).
85. Ding, J. et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103, 4198-4200 (2004).
86. Nakamura, T. et al. A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood 107, 4300-4307 (2006).
87. Kim, M. J. et al. NMr structural studies of interactions of a small, nonpeptidyl tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains. J. Biol. Chem. 282, 14253-14261 (2007).
88. Kuter, D. J. Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia. Annu. Rev. Med. 60, 193-206 (2009).
89. Adriani, M. et al. Functional interaction of common gamma-chain and growth hormone receptor signaling apparatus. J. Immunol. 177, 6889-6895 (2006).
90. De ravin, S. S. & Malech, H. L. Partially corrected X-linked severe combined immunodeficiency: long-term problems and treatment options. Immunol. Res. 43, 223-242 (2009).
91. Savage, M. O., Burran, C. P. & rosenfeld, R. G. The continuum of growth hormone-IGF-1 axis defects causing short stature: diagnostic and therapeutic challenges. Clin. Endocrinol. 72, 721-728 (2010).
92. rosenfeld, R. G. et al. Defects in growth hormone receptor signaling. Trends Endocrinol. Metab. 18, 134-141 (2007).
93. Savage, M. O. et al. Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders. Nat. Clin. Pract. Endocrinol. Metab. 2, 395-407 (2006).
94. Wojcik, J. et al. Four contiguous amino acid substitutions, identified in patients with Laron syndrome, differently affect the binding affinity and intracellular trafficking of the growth hormone receptor. J. Clin. Endocrinol. Metab. 83, 4481-4489 (1998).
95. Walker, J. L. et al. A novel mutation affecting the interdomain link region of the growth hormone receptor in a vietnamese girl, and response to long term treatment with recombinant insulinlike growth factor-1. J. Clin. Endocrinol. Metab. 83, 2554-2561 (1998).
96. Baumgartner, J. W., Wells, C. A., Chen, C. M. & Waters, M. J. The role of the WSXWS equivalent motif in growth hormone receptor function. J. Biol. Chem. 269, 29094-29101 (1994).
97. Conway-Campbell, B. L., Brooks, A. J., robinson, P. J., Perani, M. & Waters, M. J. The extracellular domain of the GH receptor interacts with coactivator activator to promote cell proliferation. Mol. Endocrinol. 22, 2190-12102 (2008).
98. Enberg, B. et al. Characterisation of novel missense mutations in the GH receptor gene causing severe growth retardation. Eur. J. Endocrinol. 143, 71-76 (2000).
99. Ayling, R. M. et al. A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat. Genet. 16, 13-14 (1997).
100. Milward, A. et al. Growth hormone (GH) insensitivity syndrome due to a GH receptor truncated after Box1, resulting in isolated failure of STAT5 signal transduction. J. Clin. Endocrinol. Metab. 89, 1259-1266 (2004).
101. Tiulpakov, A. et al. A novel C-terminal growth hormone receptor (GHr) mutation results in impaired GHr-STAT5 but normal STAT-3 signaling. J. Clin. Endocrinol. Metab. 90, 542-547 (2005).
102. Kofoed, E. M. et al. Growth hormone insensitivity associated with a STAT5b mutation. N. Engl. J. Med. 349, 1139-1147 (2003).
103. Harrison, S. M., Barnard, R. Ho, K. K. Y., rajkovic, I. & Waters, M. J. Control of growth hormone (GH) binding protein release from human hepatoma cells expressing full length GH receptor. Endocrinology 136, 651-659 (1995).
104. Barnard, R. & Waters, M. J. The serum growth hormone binding protein: pregnant with possibilities. J. Endocrinol. 153, 1-14 (1997).
105. Chernausek, S. D. et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-1 in children with severe IGF-1 deficiency due to growth hormone insensitivity. J. Clin. Endocrinol. Metab. 92, 902-910 (2007).
106. Fintini, D., Brufani, C. & Cappa, M. Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. Ther. Clin. Risk Manag. 5, 553-559 (2009).
107. Tonella, P., Flück, C. E. & Mullis, P. E. IGF-1 treatment in primary GH insensitivity: effect of recombinant human IGF-1 and rhIGF-1/ rhIGFBP-3 complex. Horm. Res. Paediatr. 73, 140-147 (2010).
108. Ogueta, S., Muñoz, J., Obregon, E., Delgado- Baeza, E. & García-ruiz, J. P. Prolactin is a component of the human synovial fluid and modulates the growth and chondrogenic differentiation of bone marrow derived mesenchymal stem cells. Mol. Cell. Endocrinol. 190, 51-63 (2002).
109. Dos Santos, C. et al. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat. Genet. 36, 720-724 (2004).
110. Wassenaar, M. J. et al. Impact of the exon-3 deleted growth hormone (GH) receptor polymorphism on baseline height and growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and metaanalysis. J. Clin. Endocrinol. Metab. 94, 3721-3730 (2009).
111. Montefusco, L. et al. d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype. Clin. Endocrinol. (Oxf.) 72, 661-667 (2010).
112. Mercado, M. et al. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly. J. Clin. Endocrinol. Metab. 93, 3411-3415 (2008).
113. Gunnell, D. J. et al. Height, leg length and cancer risk: a systematic review. Epidemiol. Rev. 23, 313-342 (2001).
114. Ahlgren, M., Melbye, M., Wohlfaht, J. & Sørensen, T. I. Growth patterns and risk of breast cancer in women. N. Engl. J. Med. 351, 1619-1626 (2004).
115. Shevah, O. & Laron, Z. Patients with congenital deficiency of IGF-1 seem protected from the development of malignancies: a preliminary report. Growth Horm. IGF Res. 17, 54-57 (2006).
116. Shen, Q. et al. Advanced rat mammary cancers are growth hormone dependent. Endocrinology 148, 4536-4544 (2007).
117. Zhang, X. et al. Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling. Carcinogenesis 28, 143-150 (2007).
118. Ikeno, Y. et al. reduced incidence and delayed occurrence of fatal neoplastic diseases in growth hormone receptor/binding protein knockout mice. J. Gerontol. A Biol. Sci. Med. Sci. 64, 522-529 (2009).
119. Samani, A. A., Yakar, S., Le roith, D. & Brodt, P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 28, 20-47 (2007).
120. Beekman, R. & Touw, I. P. G-CSF and its receptor in myeloid malignancy. Blood 115, 5131-5136 (2010).
121. Constantinescu, S. N., Girardot, M. & Pecquet, C. Mining for JAK-STAT mutations in cancer. Trends Biochem. Sci. 33, 122-131 (2008).
122. Zhu, T. et al. Oncogenic transformation of human mammary epithelial cells by autocrine growth hormone. Cancer Res. 65, 317-324 (2005).
123. Brunet-Dunand, S. E. et al. Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. Endocrinology 150, 1341-1352 (2009).
124. Perry, J. K., Mohankumar, K. M., Emerald, B. S., Mertani, H. C. & Lobie, P. E. The contribution of growth hormone to mammary neoplasia. J. Mammary Gland Biol. Neoplasia 13, 131-145 (2008).
125. raccurt, M. et al. High stromal and epithelial human GH gene expression is associated with proliferative disorders of the mammary gland. J. Endocrinol. 175, 307-318 (2002).
126. Mol, J. A. et al. Expression of the gene encoding growth hormone in the human mammary gland. J. Clin. Endocrinol. Metab. 80, 3094-3096 (1995).
127. Ergun-Longmire, B. et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J. Clin. Endocrinol. Metab. 91, 3494-3498 (2006).
128. Gebre-Medhin, M., Kindblom, L. G., Wennbo, H., Tornell, J. & Meis-Kindblom, J. M. Growth hormone receptor is expressed in human breast cancer. Am. J. Pathol. 158, 1217-1222 (2001).
129. Lincoln, D. T. et al. Up-regulation of growth hormone receptor immunoreactivity in human melanoma. Anticancer Res. 19, 1919-1931 (1999).
130. García-Caballero, T. et al. Increased expression of growth hormone and prolactin receptors in hepatocellular carcinoma. Endocrine 12, 265-271 (2000).
131. Conway-Campbell, B. L. et al. Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis. Proc. Natl Acad. Sci. USA 104, 13331-13336 (2007).
132. Lin, S. Y. et al. Nuclear localization of EGF receptor and its potential role as a transcription factor. Nat. Cell Biol. 3, 802-808 (2001).
133. Carpenter, G. & Liao, H. J. Trafficking of receptor tyrosine kinases to the nucleus. Exp. Cell Res. 315, 1556-1566 (2009).
134. Lobie, P. E., Wood, T. J., Chen, C. M., Waters, M. J. & Norstedt, G. Nuclear translocation and anchorage of the growth hormone receptor. J. Biol. Chem. 269, 31735-31746 (1994). (Pubitemid 24379543)
135. Denson, L. A. Growth hormone therapy in children and adolescents: pharmacokinetic/ pharmacodynamic considerations and emerging indications. Expert Opin. Drug Metab. Toxicol. 4, 1569-1580 (2008).
136. Fuqua, J. S. Growth after organ transplantation. Semin. Pediatr. Surg. 15, 162-169 (2006).
137. Cuatrecasas, G. Fibromyalgic syndromes: could growth hormone therapy be beneficial? Pediatr. Endocrinol. Rev. 6 (Suppl. 4), 529-533 (2009).
138. Abdel-rahman, E. & Holley, J. L. A review of the effects of growth hormone changes on symptoms of frailty in the elderly with chronic kidney disease. Semin. Dial. 22, 532-538 (2009).
139. Flores-Morales, A., Greenhalgh, C. J., Norstedt, G. & rico-Bautista, E. Negative regulation of growth hormone receptor signaling. Mol. Endocrinol. 20, 241-253 (2006).
140. Maamra, M. et al. A 36 residues insertion in the dimerization domain of the growth hormone receptor results in defective trafficking rather than impaired signaling. J. Endocrinol. 188, 251-261 (2006).
141. Brooks, A. et al. Activation of growth hormone receptor by subunit realignment. ENDO 09; The US Endocrine Society Annual Meeting, June 10-13, Washington DC, USA (2009).